Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome

    Research output: Contribution to journalLetterResearchpeer-review

  4. High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Response to Aviv et al

    Research output: Contribution to journalLetterResearchpeer-review

  2. Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent decades both combination chemotherapy and immunotherapy have been introduced. To evaluate the effects of this development, we identified all CLL patients registered in the nation-wide Danish Cancer Register between 1978 and 2013. We identified 10 455 CLL patients and 508 995 CLL-free control persons from the general population. Compared with the latter, the relative mortality rate between CLL patients and their controls decreased from 3.4 (95% CI 3.2-3.6) to 1.9 (95% CI 1.7-2.1) for patients diagnosed in 1978-1984 and 2006-2013, respectively. The improved survival corresponded to a decreasing risk of death from malignant hematological diseases, whereas the risk of death from infections was stable during the study period. These population-based data substantiate the improved survival for patients treated with chemo-immunotherapy demonstrated in clinical studies.

Original languageEnglish
JournalBlood Cancer Journal
Volume6
Issue number11
Pages (from-to)e499
ISSN2044-5385
DOIs
Publication statusPublished - 11 Nov 2016

    Research areas

  • Journal Article

ID: 49896691